Predictive Oncology CEO Discusses Corporate Milestones, Unique Approach to Cancer Research in Exclusive Broadcast
The interview can be heard at http://nnw.fm/53oiD
“Predictive Oncology and its subsidiaries, in collaboration with key players in the pharmaceutical, diagnostic and biotech industries, are finding success in several arenas,” Dr. Schwartz says. The Skyline Medical division continues to grow and expand worldwide with sales of its direct-to-drain fluid disposal system, designed specifically for medical applications, actively selling in the
The company’s TumorGenesis division has advanced its research to the point where tumors can be grown outside of the body in a medium that “fools the tumor into thinking it’s still in the body,” Dr. Schwartz explains. The advantage to this method of research is that it allows for a faster and more accurate identification of biomarkers, which can lead to development of patient-specific treatment options. Dr. Schwartz expects this revolutionary product to hit the market by year’s end.
The company’s main division, Helomics, holds the world’s largest database of tumor drug response profiles - over 150,000 tumors covering more than 137 types of cancer gathered over the last 15 years. Helomics applies AI to this rich data to aid oncologists in personalizing cancer therapy and to drive development of new, targeted therapies. Collaborative studies are underway with several renowned medical institutions and pharmaceutical firms to validate Helomic’s AI platform for several targeted cancers.
“In contrast to other companies that are just starting to do this, who then have to wait for at least four or five years to obtain patient outcomes, we already have this information going back over 10 years. This ability to access historical outcome data to complement the drug response profiles and molecular information about the tumor makes us unique,” Dr. Schwartz says. “I think that we are looking forward to a robust 2020, with a lot more to come. I would tell all of our shareholders to stay tuned.”
Listen to the full interview here: http://nnw.fm/53oiD
NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution, allows you to sit back and listen to market updates, CEO interviews and a Company AudioPressRelease (APR). These audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio (NNA) can assist your company by cutting through the overload of information in today's market, NNA brings its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire (NNW) is where news, content and information converge. NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public with an ever-growing distribution network of more than 5,000 key syndication outlets across the nation.
For more information, visit: www.NetworkNewsAudio.com
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's
Source: Predictive Oncology